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CRISPR-Cas9 System:
Opportunities and Concerns
Moderators: Stella K. Vasiliou1,2 and Eleftherios P. Diamandis1,2,3*
Experts: George M. Church,4,5 Henry T. Greely,6 Franc¸oise Baylis,7 Charis Thompson,8,9 and
Gerold Schmitt-Ulms1,10
Currently, a new revolutionary genome-editing tool
is opening new avenues for gene engineering. It is
known as the clustered regularly interspaced short
palindromic repeats (CRISPR)11 and the CRISPR-
associated (Cas) 9 system.
In general, the CRISPR-Cas system has been evolved in
archaea and bacteria as part of their adaptive immune
mechanisms. Mechanistic aspects of the system can be
found in the literature. Among the 3 CRISPR-Cas sys-
tem types that were found in these organisms, the type II
system in Streptococcus pyogenesis the most widely
applied.
The type II (CRISPR-Cas9) system includes the RNA-
guided Cas9 nuclease, which binds to specific DNA se-
quences (complementary to the RNA-guide sequence)
and creates double-stranded breaks on the DNA. The
dsDNA breaks can be repaired via homology-directed
repair (HDR) or nonhomologous end-joining (NHEJ).
Based on this principle, the Cas9 and the guide-RNA
were modified in various ways to improve the efficiency
and specificity of this system, to expand its potential for
different applications. This system can be used for alter-
ing specific genetic loci through insertions, deletions,
point mutations, and sequence inversions. More re-
cently, the system was modified to act as a genome
regulator, by tethering effector domains to the Cas9 or
guide-RNA, and as a visualization tool by fusing with
marker molecules. This multiplex capacity of engi-
neering CRISPR-Cas9 enabled scientists to apply this
system for genome modifications in a variety of organ-
isms, like Arabidopsis,Drosophila,Caenorhabditis elegans,
zebrafish, mosquitoes, mice, primates, and humans.
Lately, the CRISPR-Cas9 gene editing has been used in
human embryos and generated several ethical questions
and concerns.
In this Q&A, 5 experts from around the world discuss
the capabilities of the CRISPR-Cas9 system in editing
genomes and discuss the associated ethical concerns.
The interest for using the CRISPR-Cas9 system to
targeted genome editing is rapidly emerging. The
efficiency of this tool has dramatically improved
the last couple of years, by application of different
modifications in the Cas9 or RNA-guide molecules.
What is the importance of these new enhancements?
George M. Church: Sev-
eral modifications of Cas9
are quite impactful: (a)
switching Cas9 from a nu-
clease to an activator, (b)
making Cas9 less toxic in
stem cells, (c) increasing
HDR vs NHEJ, (d) in-
creasing specificity to the
point that single nucleo-
tide differences can be dis-
criminated routinely.
Henry T. Greely:Anything that makes the system faster,
easier, cheaper, or more accurate increases the ways it will
be used and the number of people who will use it. The
democratization of the technology—by making it cheap
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and easy enough for
poorly funded ama-
teurs—could have vast ef-
fects by making it harder
for anyone to control the
uses.
Charis Thompson: The
importance of the
CRISPR revolution is its
relative ease of use and low
startup cost and its relative
high precision to effect
targeted gene “editing.”
The fact that nearly every
academic and industry
laboratory—and some
civilian-run laboratories
and garage spaces—can
participate in this work relatively easily changes every-
thing: how fast it is being improved; how democratic
participation is; and how quickly good and bad uses
could be developed and spread.
Like all technologies, historical patterns of inclusion
and exclusion specific to given jurisdictions will tend to
be reproduced in gene editing if individual nations and
the international community do not explicitly make sure
this doesn’t happen. Efforts to fix and cure individuals’
problems will go ahead because that is how science is
already set up; the more difficult task is to get the social
architecture in place to monitor health equity, eugenics,
and environmental impact across time, place, and groups
of people, and to have the necessary correctives feed back
into the way the field develops.
Gerold Schmitt-Ulms:
The main technological
improvements to the
CRISPR-Cas9 system in
recent years are advances
in specificity, efficacy, and
range of applications. Im-
provements to specificity
minimize unpredictable
off-target effects, i.e., in-
advertent genome editing
of nonintended sites. Effi-
cacy advancements save valuable resources required to
achieve a particular outcome and are essential for certain
applications. Some of themost innovative CRISPR-Cas9
technology advances in recent years relate to the range of
applications the technology can now be used for. Its core
usage for gene knockout or precise gene editing purposes
was augmented by the identification of Cpf1 endonu-
cleases (see below). Novel applications that harness as-
pects of the system for other purposes are emerging at a
rapid pace and include its use to affect the transcriptional
control of preselected genes or visualize endogenous
genomic loci in living cells.
What are the major limitations of the CRISPR-Cas9
system?
George M. Church: (a) Very few simultaneous changes
per cell (up to 62 in one experiment in pigs, but usually
4 per cell), (b) inefficient HDR to NHEJ ratio, and (c)
efficient delivery to all cells or to a precise subset.
Henry T. Greely:This isn’t really in my expertise but I’d
suggest 2 things—the fact that it is not perfectly accurate
makes its uses more worrisome and the uncertainty about
who owns, or will own, the relevant intellectual property
could affect research and applied uses, through delay or
rushing or both.
Franc¸oise Baylis: I can
think of 2 major limita-
tions with the CRISPR-
Cas9 system: the first lim-
itation is “the user,” and
the second limitation is
“user error.”
With respect to the
first limitation, there is
reason to expect that the
science will seed fierce
competition among re-
search teams, for-profit companies, and nation states.
This competition might be similar to that which char-
acterized the 20th century’s space race and nuclear
arms race. This is not to deny the possibility of wide-
ranging collateral benefits for humankind resulting
from such competition. It is to say that we should be
wary of allowing scientific, corporate, and political
elites to dominate the relevant policy and ethical
deliberations.
With respect to the second limitation, we must be
wary of the potential consequences of off-target ef-
fects, lack of specificity in targeting, incomplete tar-
geting, and so on, all of which could have devastating
effects on patients. Here it is worth remembering that
we have no idea what most of the human genome does.
How much is due to selfish genes making copies of
themselves (transposable elements)? How much is
Q&A
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simply noise? How much is the result of retroviral
infections in our distant past? Moreover, we are only
just now beginning to investigate epigenetic influences
over gene expression. We need to be mindful of these
facts as we learn to exploit and optimize gene editing
technology.
Charis Thompson: I am a social scientist (with some life
science training) so this is not my area of expertise. From
the side of civil society, however, we will be looking for
improved nucleases to increase safety and efficacy. In
particular, the improved nucleases hold promise for re-
ducing off-target effects, which would improve the effec-
tiveness of the target gene edit, and reduce unintended
consequences. Greater accuracy will also improve our
ability to characterizemechanism and tomonitor efficacy
and safety, including over multiple generations.
Gerold Schmitt-Ulms: Major limitations of initial
CRISPR-Cas9 systems were the frequent occurrence of
inadvertent off-target effects. Several technology im-
provements, including the availability of assays for
genome-wide identification of off-targets and improved
algorithms for selecting target sites, improved this short-
coming. However, the advent of Cas9 nickases, in which
1 of 2 endonuclease modules within the Cas9 protein is
rendered inactive by point mutation, resulted in the most
dramatic improvement. When combined with pairs of
guide RNAs targeting nearby sites on opposite strands,
the nickase approach greatly improved target site speci-
ficity. Taken together, these advancesmake limitations in
the system’s efficacy the most pressing bottleneck at this
time. The latter can be further crudely subdivided into
limitations related to its delivery to cells and limitations
that relate to the rate of gene editing itself. The delivery
problem is not unique to CRISPR-Cas9 systems but
also poses a formidable challenge to the clinical use of
transcript knockdown technologies. Similarly, limita-
tions in the rate of CRISPR-Cas9—mediated gene
editing are also encountered with other gene editing
technologies, such as those based on transcription
activator-like effector nucleases (TALEN). While
these limitations are less pronounced with CRIPSR-
Cas9 systems than with alternative gene editing strat-
egies, they still force a workflow that relies on relatively
time-consuming downstream selection steps for the
isolation of clones that have undergone the desired
gene-editing step.
Like Cas9, Cpf1 is another single RNA-guide nuclease of
the type II CRISPR-Cas system. What is the importance
of using improved nucleases with this system?
George M. Church: We have not found Cpf1 to be an
“improved nuclease” (yet). In contrast, the 4 modifica-
tions to the Cas9 system listed in question 1 have been
significant improvements.
Gerold Schmitt-Ulms: The discovery of the CRISPR-
Cpf1 technology is promising for several reasons.
Whereas Cas9 requires 2 RNAmolecules to direct it to its
DNA cut sites, Cpf1 requires only one guide RNA and is
a smaller protein, which facilitates getting the system into
cells. Most importantly, however, Cpf1 generates stag-
gered cuts (as opposed to blunt ends by Cas9), which
make it an attractive endonuclease for achieving true gene
edits in nondividing cells in which the cell-autonomous
homology-directed repair mechanism is not working ef-
fectively. The recent discovery of C2c2, a naturally oc-
curring RNA-guided enzyme that targets RNAs, adds yet
another exciting capability to the tool box of molecular
biologists.
Experiments in humans are currently restricted.
However, gene-editing of some sort in human cells has
been applied in research for decades. The use of the
CRISPR-Cas9 system in human embryos by a Chinese
group started a debate regarding the application of
this technology to humans. Also, a UK investigator
was recently approved to use this system for modifying
embryonic stem cells. What is your opinion on this
issue?
George M. Church: Ironically, the first paper from
Prashant Mali, Luhan Yang, and coworkers (Science
2013;339:823–6) on using CRISPR in nonbacterial cells
used human stem cells, which were probably more capa-
ble of producing viable human embryos than were the
triploid cells used in the study reported from Junjiu
Huang (China) (Protein Cell 2015;6:363–72). Also, the
mitochondrial germ-line engineering (from Shoukhrat
Mitalipov’s laboratory in Oregon) involved human em-
bryos and was aimed at therapy. The UK embryo work
(from Kathy Niakan’s lab) was aimed at basic biology,
not gene therapy. So it is odd that the Chinese and UK
experiments are discussed as if they were more problem-
atic than the Oregon and Harvard experiments. All 4 of
these experiments are legal in most countries, including
US, UK, and China. Gene editing is not just used in
human cells or embryos, but also in approved clinical
trials (human adults and children).
Henry T. Greely: I’m in favor of any well-conducted
research with CRISPR-Cas9 (or similar systems) that
does not use it to change living people or human cells that
are intended to become living people (gametes, embryos,
or fetuses). I’m in favor of well-conducted and regulated
research to use these techniques to modify the somatic
cells of people to treat disease, as well as clinical use if
and when proven safe and effective. I think we need to
Q&A
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talk more as societies about possible uses in living peo-
ple not to treat disease but for “enhancement,” bearing
in mind that we don’t have a clue how to make su-
perbabies or how to do even minor enhancements. I
am against using it to make inherited changes unless or
until that technique is proven, by high standards, to be
both safe and effective, at which point my reaction is
similar to my reaction to somatic cell uses in existing
people.
Franc¸oise Baylis: Ethical concerns about germline gene
editing can usefully be clustered into 2 categories: con-
cerns about any and all research involving human em-
bryos and concerns specific to gene editing involving hu-
man embryos. In the first category there are concerns
about the moral status of the developing human embryo,
as well as concerns about the source of the embryos used
for research purposes—for example, whether proper con-
sents were obtained, and whether women egg providers
were exploited.
In the second category there are myriad concerns
about the introduction of heritable modifications should
any of themanipulated embryos be used in reproduction.
There are concerns about the risk of errors and (unin-
tended) consequences, not only for the resulting
child(ren) but also for humankind. In the latter context
there are concerns about the risk of exacerbating prob-
lems of racism, sexism, health inequality, and so on, as a
direct consequence of who will and who will not have
access to the technology. In addition, there are wide-
ranging objections to this research grounded in the belief
that we should not be tinkering with the “patrimoine
ge´ne´tique” (which is a reference to the human genome as
the heritage of humanity). The worry here is that some
among us will boldly go where no one has gone before in
selecting modifications for the population at large,
thereby possibly irretrievably altering the human species.
Charis Thompson:My opinion is that the current con-
sensus in the UK is right. That is, I agree that appropri-
ately consented and procured human embryos [exited
from reproductive projects in assisted reproductive ther-
apy (ART) clinics] can be gene edited to learn about basic
biology, to improve gene editing procedures and mecha-
nisms, and to understand failures of pregnancy (cf Kathy
Niakan’s research), but edited human embryos should
not at this point be implanted in any woman’s womb
with the intention of establishing a pregnancy. More ev-
idence that gene editing is accurate and safe and effica-
cious needs to be accumulated before implantation.
Should the needed evidence build up, however, I
would not be averse to using gene editing for reproduc-
tive purposes if the correct social architecture was in place
to monitor and counteract tendencies to become select-
ing and/or inequitable. I call this position CRISPR:
(Currently restrict implantation; someday permit repro-
duction). People with disabilities and those who tend to
bemedically disenfranchised (low income, migrant, non-
citizens, racialized others, etc.) should lead the conversa-
tion in what kinds of selecting and access and uses are
acceptable. The disability justice slogan, “Nothing about
us without us” should be the guiding philosophy.
Gerold Schmitt-Ulms: I am in favor of transparent re-
search to explore the strengths and limitations of
CRISPR-Cas9 and related systems in human cells, in-
cluding in nonviable human embryos (e.g., with major
chromosomal anomalies). These experiments will not
only help us better understand the risks associated with
the use of this technology but will also generate insights
into the function of proteins and their role in early hu-
man development. The widespread fear that these exper-
iments are the precursor to inevitable future uses of the
technology in human genome engineering seems over-
blown. The ability to combine in vitro fertilization with
the selection of embryos devoid of a particular disease-
causing mutation to overcome inherited monogenic dis-
eases already exists. It is difficult to see how undertaking
CRISPR-Cas9 genome edits in reproductive cells (also
known as germ-line editing), an inherently more inva-
sive technology, could supersede this safer approach. A
more realistic scenario might be that lessons learned
from CRISPR-Cas9 experimentation with human
cells prompt the use of this technology in the correction
of disease-causing mutations in somatic cells. If such an
application were to become a reality, it would need to be
preceded by a rigorous safety evaluation in combination
with a global ethics debate involving stakeholders from
all facets of society and not just the scientific community.
If the CRISPR-Cas9 system becomes 100% safe and
effective, what are the potential ways of utilizing this
technology to correct human heritable diseases?
George M. Church: Parents who are carriers of serious
genetic diseases (like Tay-Sachs) could use gene editing of
sperm or egg producing cells, rather than putting em-
bryos at risk of abortion (or nonimplantation in in vitro
fertilization).
Henry T. Greely: First, you could, at least in many cases,
edit the somatic cells of people (or, even when shown safe
and effective, fetuses and embryos) to prevent the disease.
If this does not become sufficiently safe and easy, germ-
line modification may not be attractive. Second, you
could modify the germline, either by modifying a “future
person’s” entire body by making modifications in the
gametes or embryos that becomes the person, or by mod-
ifying a living person’s eggs and sperm so the disease
alleles will not be passed on. Frankly, there are very, very
Q&A
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few times that genome editing would be needed to avoid
passing on a genetic disease; using preimplantation ge-
netic diagnosis, a procedure with which we have more
than 25 years of experience, to select embryos that do not
carry the disease-causing genes will almost always be suf-
ficient. (Formore on embryo selection, see my new book,
The End of Sex.)
Franc¸oise Baylis: As worded, there are at least 3 signifi-
cant problems with this question. First, nothing is 100%
safe and effective and this is not the standard for moving
from clinical research to clinical practice. In effect, a par-
ticularly interesting and challenging question is how
much safety and how much effectiveness should be re-
quired before patients are offered innovative technologi-
cal interventions?
Second, safety and effectiveness are not the only rel-
evant criteria. A new intervention could be “safe enough”
and “effective enough,” but trivial in the grand scheme of
things and, as a result, not worth the investment of time,
talent, and resources. Persons seriously contemplating
the use of germ line gene editing to correct a heritable
disease will need to carefully consider the nature of the
health condition they aim to correct, as well as the avail-
ability of alternative, safer treatment options.
Third, there is no agreement on which, if any, hu-
man heritable diseases should be corrected. Consider, for
example, debates around ableism or overpopulation
alongside debates about available, safer options for pro-
moting the birth of so-called healthy children.
Charis Thompson: I think that we should move slowly
and focus on monogenic and oligogenic diseases for
which there is not already a good somatic treatment first.
We should also stand by a principle I have called the
cure–care parity principle, so that we invest equally in
improving care and accommodations and access and
don’t focus all our attention on some fictive idea of all
being cured from what ails us.
Wemust also make sure that we empower those best
placed to talk about what things are diseases and what
things are only diseases seen from a narrow and a histor-
ical point of view. No one has the right to say whether or
not someone else’s life is intrinsically worth living. We
know from prenatal screening that weeding out differ-
ence happens all too easily; today people abort for much
more minor deviations than in the past.
Gerold Schmitt-Ulms: Due to the inherent complexity
of natural systems, a technology of this nature can never
be completely safe. But risk–benefit considerations may
indicate its use in certain cases provided there are no
ethical concerns. Two major uses of this technology to
address inherited diseases can be identified: genome ed-
iting of reproductive human cells (also known as germ-
line editing) or the correction of mutations in somatic
cells. The first application refers to correcting the herita-
ble disease in a manner that would eradicate the risk to
subsequent generations and would be undertaken at the
earliest possible embryonic stage. A somatic correction
would most likely be directed to a subpopulation of cells
that are both accessible and critical for the manifestation
of the most severe disease symptoms but would not im-
pact inheritability of the disorder.
Do you believe that this system or alternatives will
ever be used to improve the human race in terms of
appearance and intellectual capacity, etc. (eugenics)?
George M. Church: Cosmetics and coffee have been in
wide use for decades to affect appearance and cognitive
features, but would we rank these as major improvements
in the human race? Truly major biological augmenta-
tions include global elimination of smallpox and reduc-
tion in childbirth-associated deaths. We will probably
improve cognition via drugs aimed at reducing cognitive
decline in our increasingly aged population. This may not
involve gene editing but could nevertheless impact many
generations. The context of eugenics has changed com-
pletely since the time (up until the 1970s) that many coun-
tries, including the US and Sweden, forced sterilizations. In
contrast, gene therapy is about giving people more choices.
Henry T. Greely: Clearly yes, in one sense. Avoiding
certain genetic diseases will improve appearance and in-
tellectual capacity. But assuming you mean apart from
treating diseases, I suspect some people will eventually
use methods for genetic enhancement—after we figure
out what genetic variations actually “enhance” us, some-
thing we know almost nothing about. My own guess is
that embryo selection will be used much more rapidly
and commonly than genomic editing, but in the long run
both are likely to be used. Whether that would deserve
the term “eugenics” depends in part on what you think
that word means—any selection, or government-
enforced selection? (Or, as happened in the past but is
highly unlikely in the future, in part because of CRISPR-
Cas9, government-enforced sterilization.)
Franc¸oise Baylis: While there are some “disease genes”
we might all agree should be eradicated, I don’t think we
know (or can know) what will improve the human spe-
cies. Traits that seem important and useful to us today
may prove to be irrelevant and perhaps even disadvanta-
geous in the not too distant future. Regardless, at least
some among us remain enthralled by the prospect of
human enhancement.
I have argued elsewhere, and continue to believe,
that human genetic enhancements are inevitable. This
perspective is informed by a particular view of human
Q&A
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nature having to do with capitalism, heedless liberalism, a
drive for knowledge, a desire to outperform, and a fair
amount of hubris allowing us to believe that “the future is
ours for the shaping.” This claim about the inevitability
of genetic enhancements is descriptive, not normative,
and aims to motivate careful reflection on the ways in
which we can use our intellect, our energy, and our finan-
cial resources in pursuit of the common good.
Charis Thompson: Yes, I think that people are already
thinking about this. It is all the more urgent to build the
social architecture in proactively, so that the social inno-
vation is just as important as the scientific innovation.
Luckily, many kinds of intelligence are valued and nec-
essary, and many kinds of looks are, too. We have to
make sure that we stop tiny segments of the population
imposing their ideas on the rest of us by making social
monitoring and assessment and correction an intrinsic
and nonvoluntary part of the research infrastructure.
There are very important conversations to be held
and monitoring to be ongoing about, for example, which
military uses of gene editing for certain kinds of physical
and intellectual abilities need what kind of lay scrutiny.
Similarly, pure majoritarianism does not work in this
realm; protection of minority rights is central and essen-
tial. The latter is a poorly attended-to part of democracy;
moving forward, it should be central.
Gerold Schmitt-Ulms: I am categorically opposed to the
use of this technology in humans for the pursuit of non-
medical objectives, and I am not aware of any reasonable
person who would advocate it. However, I am less con-
fident that it won’t eventually be tried. Similar to ongo-
ing global efforts to minimize the risk of nuclear wars, the
abuse of CRISPR-Cas9-related technologies for eugenics
needs to carry a sufficiently high penalty to discourage it. As
with the ongoing threat of a nuclear catastrophe, this chal-
lengewill not go away. It is the collective responsibility of the
global society tomonitor and prevent the abuse of this tech-
nology for applications that lack moral foundation.
The CRISPR-Cas9 system is capable of altering the
genome of any organism in this planet. Scientists have
used it for various research purposes and it is also
capable of improving food quality and production,
resulting in the increase of diversity among species.
Could you highlight your environmental concerns?
George M. Church: Since 2014, I have been drawing
attention to the concern about the need for safety strate-
gies for gene drives and for surveillance for people not
employing such strategies. Increased diversity is often as-
sociated with healthy ecosystems, but each intentional
release of new organisms into the wild (whether by “nat-
ural” random mutation, by transgenics, or by nontrans-
genic editing) should be carefully assessed first.
Henry T. Greely: Modified organisms might harm the
environment, whether through an accidental escape from
the laboratory or intentional release. Think of your least
favorite invasive species—kudzu, Dutch elm disease, the
starling in the US, the rabbit in Australia. Genomic en-
gineering could produce more. Even worse, terrorists (or
criminals) could use this to make pathogens for biowar-
fare or extortion. I’m excited about the nonhuman uses
but they need to be known in advance, regulated, and
followed after release.
Franc¸oise Baylis: As Branden Allenby and Daniel Sare-
witz explain, in their recent writings on the techno–
human condition, we are part of a very complex net-
worked system, the boundaries of which are difficult to
determine. Try as we might, the ecosystem we inhabit is
not subject to our understanding or control (viz. expo-
nential population growth, finite space, limited re-
sources, climate change).We act, however, as if this com-
plex networked system was merely “complicated, messy,
less predictable or understandable” than it might other-
wise be. In addressing the complexity, messiness, and
unpredictability, we erroneously assume a certain order
and take comfort in the use of tools we have engineered to
achieve clearly defined goals. This orientation explains,
in part, intentional actions with unintended conse-
quences, such as the introduction of rabbits and poison-
ous toads in Australia, mongoose in the Hawaiian Is-
lands, purple loosestrife in New Zealand, and kudzu in
the US.
All of this to say that we err in presuming an ordered
determined world where we can simply take over the
evolutionary story. Ours is a very complex networked
system and we forget this at our peril. We need consid-
erably more humility in contemplating whether to put
our oar in waters that are not merely opaque and turbu-
lent, but unfathomable.
Charis Thompson:My sense is that the environment is
generally quite capacious and can tolerate gene tinkering
because it is the way of “natural” evolution, but we are on
the cusp of several tipping points (extinction, fresh water
depletion, catastrophic climate change) so even small en-
vironmental destabilizations should be treated very care-
fully. Diversity per se is not necessarily a good thing itself,
if it comes without the benefits of coevolution, including
ecological niche, a degree of immunity, and intergenera-
tional survival.
Gerold Schmitt-Ulms: Humans have continually al-
tered the environment ever since they abandoned their
hunter–gatherer lifestyle. Over time we have learned to
Q&A
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improve harvest yields by techniques ranging from care-
ful selection to genetic manipulation. CRISPR-Cas9–
related genome engineering could profoundly accelerate
our ability to shape the natural world around us. I am
highly critical of such an interventionist approach that
sets free gene-manipulated organisms at this time because
of our rudimentary understanding of the complex bio-
logical interplay of the environment. Currently, a com-
pelling argument cannot be made that genetically modi-
fied crops are essential for human survival. Instead, I
would argue that existing food shortages are not the con-
sequence of a fundamental scarcity of foods but a result of
unequal distribution. However, I am not fundamentalist
in this matter and, just as I am supportive of responsible
research that explores the use of CRISPR-Cas9–related
technologies to improve human health, I am also sup-
portive of efforts to understand how food sources could
be improved through genetic manipulation. Undertaken
responsibly, this research may teach us lessons that could
become essential for human survival in the future.
What do you think will be the most useful clinical/
societal application of this or a similar system in the
future?
George M. Church: (a) Reducing risk to embryos and
abortions—spontaneous and induced (see question 5),
(b) gene drives for malaria (see question 9), and (c) in-
creasing safety of xenotransplantation.
Henry T. Greely: It should greatly improve our ability to
manipulate life, to feed and to provide energy for humans
while preserving and even restoring or otherwise improv-
ing the environment. It should help make classic gene
therapy, which has been 5 years in the future for the past
35 years but now really is close, better. And it may be
useful in surprising ways to help stop infectious diseases
(changemosquitoes to stopmalaria) ormake better use of
our microbiomes for our own health and comfort.
Franc¸oise Baylis: The most useful clinical application of
CRISPR-Cas9 or a similar system will be for the somatic
cell treatment of single-gene defects that result in condi-
tions that are lethal within the first weeks to years of life.
This is a very small set of conditions.
I can’t even begin to imagine the most useful societal
application of CRISPR-Cas9 or a similar system given
my beliefs about the complexity of the world in which we
live, and my concerns about the hubris motivating those
who embrace volitional evolution.
More generally, in thinking about possible clinical
and societal benefits, it is worth thinking about useful
preclinical applications of CRISPR-Cas9 or a similar sys-
tem. Gene editing technology does not have to be used to
directly correct a gene abnormality in a human. It can be
used in cell-based and preclinical animal models (like
zebrafish) to replicate specific humanmutations to better
understand the biology and to test therapeutics. This
could lead to less controversial, less risky, and more effec-
tive therapeutic interventions.
Charis Thompson: I think CRISPR is most useful for
the basic biology it is revealing; I have no doubt that all
kinds of clinical and societal dimensions of this will un-
fold in the years to come. I think the second most impor-
tant is in drug discovery, including moving slowly but
surely from animal models toward in vitro humanized
organoid dish models. Finally, I think there is the poten-
tial to rid us of some of the more debilitating diseases that
are currently fatal. It is vital, however, that the voices of
those living with the diseases or traits or differences in
question be central in any decision-making apparatus
about which conditions to use gene editing for.
Gerold Schmitt-Ulms: The most useful application of
this technology for human health and society will be in
translational research. Amongst a myriad of potential ap-
plications, the ability to model critical aspects of diseases
in eukaryotic cells or model organisms stands out. This
unprecedented access to disease models will help us dis-
sect the complex molecular interactions underlying dis-
eases and, in turn, will greatly support ongoing efforts to
derive selective diagnostics and treatments for them.
A profound long-term benefit of this technology
may emerge from the manipulation of eukaryotic patho-
gens or the vector organisms transmitting them with a
view to selectively disarm or ameliorate their human
pathogenicity. The list of diseases this general concept
could be applied to is long, and it includes prevalent
diseases in the tropics and temperate regions, including
malaria, leishmaniasis, dengue fever, and Lyme disease.
However, this potential application raises profound eth-
ical questions and technical challenges. Before releasing
genetically engineered organisms into the wild, it will be
critical to verify that the engineered genetic element de-
signed to spread in a population does not cause undesired
disturbances to the ecosystem of the respective pathogen
or vector. Compared to other pathogen eradication strat-
egies that have been applied in the past, including vacci-
nation programs or the wide-spread use of pesticides, this
approach may eventually not only become more effective
but may also prove to be more enduring and to cause less
ecological damage.
Could this technology favor the rich people, to in-
crease their advantage over the poor?
George M. Church: Yes or it could be used to greatly
help the poor. It is up to all of us to work hard toward the
latter. Examples: (a) CRISPR-gene-drives are probably
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far less expensive than vaccines and classical (small-
molecule) antibiotics, which have not been ideally effec-
tive for malaria, dengue, and nematode diseases—which
afflict millions of the poorest people in the world. (b)
Genome sequencing has come down in price 3-million-
foldandcontinuestodrop—providingpreventativemedi-
cine that canbemuchmore affordable than reactivemedi-
cine or no medicine. (c) For people who can only afford
bareminimal foods, agricultural advances like golden rice
could save millions of lives.
Henry T. Greely: It could if we let it, which makes it no
different from any other useful technology. Vigilance will
be needed, not of the technology but of the society.
Franc¸oise Baylis: The challenge in answering this ques-
tion is whether to think about this intranationally or
internationally. If somatic gene editing ever becomes a
safe and effective therapeutic intervention for one or
more discrete conditions, there is reason to believe that it
will only be available in high- and some middle-income
countries. I cannot imagine this as a priority in countries
that struggle to provide their population with access to
basic healthcare.
In response to this concern some will argue that, as
with other technologies, in time, somatic gene editing
will be affordable for the masses. This is hard for me to
imagine, however. In a country like the US that does not
have a universal healthcare system, I can’t see the masses
having access to this kind of personalized medicine. As
well, I expect the same will be true for countries with
universal healthcare. Public health needs will always be a
priority over personalized medicine.
As such, somatic gene editing does not raise new
health equity issues, but rather exacerbates existing social
injustice both inter- and intranationally. In a world that
joyfully embraces capitalism it is hard to know how best
to address this issue. In all aspects of life, the rich have an
advantage over the poor as they can purchase what others
can only dream of, and frequently they do so with impunity
(oblivious to the harmful consequences of their actions).
Charis Thompson: Yes, especially in countries without
universal healthcare but with biomedical investment
(most notably the US, but also many other countries),
this technology is likely to fall into existing patterns of
discrimination and inequity, unless we explicitly prevent
it from doing so (see above). The crucial elements are to
have the right people opt in—starting with those with the
condition in question and those without vast resources at
the table—and to make sure that monitoring is compre-
hensive and that these social monitoring bodies have real
teeth, being able to intervene and correct the path that
individual, biomedicalizing (or industry or military) re-
search is going.
Gerold Schmitt-Ulms: It is a sad truism that technolog-
ical advancements generally tend to benefit wealthier seg-
ments of societies first. This technology will be no excep-
tion, and it is to be expected that access to certain
CRISPR-Cas9 applications will first become available in
places that have a well-functioning healthcare system.
Individual benefits of this nature may manifest
through genome editing of somatic cells in several spe-
cific diseases. For example, if one could restore the wild-
type allele coding for the cystic fibrosis transmembrane
conductance regulator protein in a small percentage of
lung epithelial cells of individuals afflicted with cystic
fibrosis, a pronounced benefit for their lung functions
would be expected. Similarly, in certain immunodeficiency
diseases or leukemias caused by mutated hematopoietic
stem cells, CRISPR-Cas9 might be employed to restore the
wild-type gene sequence underlying the disease.
Fortunately, the 2 areas in which this technology
may have the most pronounced impact, (i) its ability to
greatly accelerate our understanding of the biological
world around us, including how to diagnose and treat
diseases, and (ii) the possibility it offers for subtly chang-
ing our environment to disarm pathogens or the vectors
that transmit them, are of such a nature that they may
eventually benefit all. Thus, compared to the challenges
posed by the potential abuse of this technology, unequal
opportunities to access this technology for specific per-
sonalized medical applications may be a relatively small
concern.
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